Polymorphism of debrisoquine oxidation in New Zealand Caucasians
- 1 March 1992
- journal article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 42 (3) , 349-350
- https://doi.org/10.1007/bf00266364
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populationsEuropean Journal of Clinical Pharmacology, 1990
- Evidence for the polymorphic oxidation of debrisoquine in the Thai population.British Journal of Clinical Pharmacology, 1990
- OXIDATION PHENOTYPING IN CHINESE AND MALAY POPULATIONSClinical and Experimental Pharmacology and Physiology, 1988
- LOW FREQUENCY OF SLOW DEBRISOQUINE HYDROXYLATION IN A NATIVE CHINESE POPULATIONThe Lancet, 1987
- Debrisoquine oxidation in an Australian population.British Journal of Clinical Pharmacology, 1986
- Sparteine Oxidation Polymorphism in DenmarkActa Pharmacologica et Toxicologica, 1985
- Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populationsClinical Pharmacology & Therapeutics, 1985
- Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in manEuropean Journal of Clinical Pharmacology, 1984
- Ethnic Differences in Drug MetabolismClinical Pharmacokinetics, 1982
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980